The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The blood screening market is an essential part of modern healthcare, helping ensure that blood used for transfusions and medical procedures is safe and free from infectious diseases. By detecting viruses like HIV, hepatitis B and C, and other harmful pathogens, blood screening protects both donors and recipients. With the growing number of surgeries, organ transplants, and blood donations, the demand for reliable and accurate screening methods continues to rise. As technology advances and awareness about blood safety increases, the market is expected to grow steadily, playing a crucial role in maintaining public health and improving patient outcomes.

Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/blood-screening-market-102552

Blood Screening Market Overview:

The Blood Screening Market plays a vital role in modern healthcare by ensuring the safety of blood used for transfusions, surgeries, and donations. It involves testing for infectious diseases, genetic disorders, and other abnormalities to prevent the spread of conditions like HIV, hepatitis B and C, and syphilis. With the rising demand for safe blood supplies and increasing public awareness, the market continues to gain significant traction worldwide.

Market Trend

A key trend driving the Blood Screening Market is the growing adoption of nucleic acid testing (NAT), which offers higher sensitivity and faster detection of bloodborne pathogens. Automation and integration of advanced technologies in screening platforms are also on the rise, helping laboratories improve accuracy and throughput. Moreover, the trend of decentralized testing in blood banks and community healthcare centers is gaining popularity, making screening more accessible and efficient.

Market Segmentation:

The blood screening market can be segmented based on technology, product and service, application, and end-user.

By Technology:

The market is divided into nucleic acid testing (NAT), ELISA, rapid tests, and western blot assays. Among these, NAT holds the largest share due to its high precision in early detection of infections. ELISA remains widely used for routine screening owing to its affordability and ease of use, especially in resource-limited settings.

By Product and Service:

The blood screening market offers reagents and kits, instruments, and software & services. Reagents and kits account for the largest revenue share, driven by their recurrent demand and continuous need in testing procedures. Meanwhile, automation in instruments and the integration of data management software are improving workflow efficiency and reducing human error.

By Application:

In terms of application, the blood screening market is primarily used for infectious disease detection, blood grouping, and genetic screening. Infectious disease testing dominates the segment due to the critical need to prevent transfusion-related infections. Genetic and prenatal screening are also gaining attention, especially in developed regions with advanced diagnostic capabilities.

By End-User:

The blood screening market serves blood banks, hospitals, diagnostic laboratories, and research institutions. Blood banks represent the largest end-user segment as they are central to collecting and screening donated blood. Hospitals are increasingly investing in in-house screening facilities to reduce dependency and turnaround times, while diagnostic labs focus on expanding testing portfolios for a wider range of diseases.

List Of Key Companies Profiled:

Market Growth

The blood screening market is witnessing robust growth, fueled by a surge in the number of blood donations, the increasing prevalence of transfusion-transmissible infections, and rising healthcare expenditure globally. Government initiatives promoting voluntary blood donations and mandatory screening protocols are also boosting market expansion. Furthermore, the rise in organ transplants and surgical procedures has intensified the need for reliable and rapid blood testing solutions.

Restraining Factors:

Despite its promising growth, the blood screening market faces several challenges. High costs associated with advanced screening technologies can be a barrier for smaller clinics and blood banks, especially in developing countries. Additionally, the lack of skilled professionals and infrastructure in rural regions limits the widespread implementation of sophisticated testing methods. Regulatory complexities and delays in product approvals also pose hurdles to new entrants in the market.

Regional Analysis:

North America leads the blood screening market due to its well-established healthcare infrastructure, high awareness levels, and strong government support for safe blood transfusion practices. Europe follows closely, with growing demand for advanced screening technologies and rigorous regulatory standards. In Asia-Pacific, the market is expanding rapidly, fueled by increasing healthcare investments, a large population base, and rising awareness about blood safety. Countries like India and China are showing strong potential for growth, supported by government campaigns and the expansion of healthcare facilities in urban and semi-urban areas.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com